for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Abeona Therapeutics Inc

ABEO.OQ

Latest Trade

2.24USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.46

 - 

10.83

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.24
Open
--
Volume
--
3M AVG Volume
23.32
Today's High
--
Today's Low
--
52 Week High
10.83
52 Week Low
1.46
Shares Out (MIL)
49.32
Market Cap (MIL)
110.47
Forward P/E
-1.25
Dividend (Yield %)
--

Latest Developments

More

Abeona Therapeutics Provides Regulatory Update Ahead Of Pivotal Phase 3 Clinical Trial For EB-101 In Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics Announces Strategic Review

Abeona Therapeutics Reports Q2 Loss Per Share $0.49

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Abeona Therapeutics Inc

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

Industry

Biotechnology & Drugs

Contact Info

1330 Avenue of the Americas Fl 33

+1.646.8134701

https://abeonatherapeutics.com/

Executive Leadership

Steven H. Rouhandeh

Executive Chairman of the Board

Timothy J. Miller

President, Chief Scientific Officer

Joao Siffert

Chief Executive Officer, Director

Christine Berni Silverstein

Chief Financial Officer

Edward Carr

Chief Accounting Officer, Vice President

Key Stats

2.50 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.640

2017

-0.660

2018

-1.190

2019(E)

-1.786
Price To Earnings (TTM)
--
Price To Sales (TTM)
50.42
Price To Book (MRQ)
1.03
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-51.82
Return on Equity (TTM)
-46.84

Latest News

Latest News

BRIEF-Abeona Announces FDA Grants Rmat Designation To ABO-102 Gene Therapy In MPS Iiia

* ABEONA ANNOUNCES FDA GRANTS RMAT DESIGNATION TO ABO-102 GENE THERAPY IN MPS IIIA

BRIEF-Abeona Therapeutics Receives Orphan Drug Designation In The European Union For ABO-202 Gene Therapy Program In Batten Disease

* ABEONA THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ABO-202 GENE THERAPY PROGRAM IN BATTEN DISEASE Source text for Eikon: Further company coverage:

BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer

* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER

BRIEF-Abeona Therapeutics Appoints Carsten Thiel As Chief Executive Officer

* TIMOTHY J. MILLER WILL REMAIN PRESIDENT AND ASSUME POSITION OF CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage:

BRIEF-Abeona Therapeutics Reports Q4 Loss Per Share $0.19

* ABEONA THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

BRIEF-Abeona Receives FDA Rare Pediatric Disease Designation For ABO-202 Gene Therapy Program In CLN1 Disease

* ABEONA THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN CLN1 DISEASE

BRIEF-Abeona Receives FDA Orphan Drug Status For Gene Therapy To Treat Rare Disease In Newborns

* ABEONA THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN INFANTILE BATTEN DISEASE

BRIEF-Abeona Therapeutics Says Gene Therapy ABO-101 Is Well Tolerated

* ABEONA THERAPEUTICS REPORTS ON INITIAL SAFETY AND BIOPOTENCY SIGNALS IN MPS IIIB GENE THERAPY CLINICAL TRIAL

BRIEF-Abeona Receives FDA Regenerative Medicine Advanced Therapy Status For Experimental Gene Therapy For Rare Skin Disorder

* ABEONA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR EB-101 GENE THERAPY IN EPIDERMOLYSIS BULLOSA

BRIEF-Abeona Q3 loss per share $0.13

* Abeona reports third quarter 2017 financial results and recent business highlights

BRIEF-Abeona Therapeutics prices offering of five million shares at $16 per share

* Pricing underwritten public offering of five million shares of common stock at a public offering price of $16.00 per share Source text for Eikon: Further company coverage:

BRIEF-Abeona Therapeutics announces public offering of common stock

* Abeona Therapeutics announces public offering of common stock Source text for Eikon: Further company coverage:

BRIEF-Abeona Therapeutics to receive $13.85 mln of grants for development of Sanfilippo gene therapy programs​

* Abeona Therapeutics Inc - nine global foundations collaborate to grant $13.85 million for continued advancement of lead Sanfilippo gene therapy programs Source text for Eikon: Further company coverage:

BRIEF-Abeona Therapeutics enrolls first two patients in phase 1/2 clinical trial in MPS IIIA

* Abeona Therapeutics enrolls first two patients in pivotal expansion of phase 1/2 clinical trial in MPS IIIA

BRIEF-ABEONA ANNOUNCES TOP-LINE ONE YEAR DATA FROM ABO-102 MPS IIIA TRIAL

* ABEONA ANNOUNCES TOP-LINE ONE YEAR DATA FROM ABO-102 MPS IIIA TRIAL AT ARM’S CELL & GENE MEETING ON THE MESA

BRIEF-Viking Global Investors reports 5.6 percent passive stake in Abeona Therapeutics

* Viking Global Investors Lp reports 5.6 percent passive stake in Abeona Therapeutics Inc as of Sept 22 - SEC filing Source: (http://bit.ly/2yEgWSq) Further company coverage:

BRIEF-Abeona Therapeutics and Brammer Bio announce collaboration for commercial translation of ABO-102

* Abeona Therapeutics and Brammer Bio announce collaboration for commercial translation of ABO-102

BRIEF-Adage Capital Partners reports 5.4 pct passive stake in Abeona Therapeutics

* Adage Capital Partners LP reports 5.40 pct passive stake in as of Sept 6 - SEC filing Source text: [http://bit.ly/2yddoHo] Further company coverage:

BRIEF-Abeona Therapeutics receives FDA breakthrough therapy designation for EB-101

* Abeona Therapeutics receives FDA breakthrough therapy designation for EB-101 autologous cell therapy in Epidermolysis Bullosa

BRIEF-Abeona Therapeutics expands gene therapy clinical trials in Sanfilippo Syndrome Type A

* Abeona Therapeutics announces pivotal expansion of ABO-102 gene therapy clinical trials in Sanfilippo Syndrome Type A

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up